Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Asciminib

Lack of efficacy following off-label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Khadadah FM, et al. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia Research 133 : 1-7, Oct 2023. Available from: URL: https://www.elsevier.com/locate/leukres Khadadah FM, et al. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia Research 133 : 1-7, Oct 2023. Available from: URL: https://​www.​elsevier.​com/​locate/​leukres
Metadaten
Titel
Asciminib
Lack of efficacy following off-label use: 3 case reports
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49010-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Antineoplastics

Case report

Amitriptyline